AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25761431 — intervention group
Group type: COMPARATOR
Intervention: Survey controls
Number of subjects: 937
Study 25761431 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled participants
Number of subjects: 937
Study 25761431 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen fails
Number of subjects: 937
Study 25761894 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 32
Study 25761894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 32
Study 25762180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib (SB1518)
Number of subjects: 35
Study 25762240 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Mesh (OM) hernioplasties
Number of subjects: 335
Study 25762240 — intervention group
Group type: COMPARATOR
Intervention: Open Non-mesh (OS) repairs
Number of subjects: 335
Study 25762240 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic (LAP) repairs
Number of subjects: 335
Study 25762343 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7356 (humanized anti-CD44 antibody)
Number of subjects: 0
Study 25762355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy using the body composition monitor (BCM)
Number of subjects: 1092
Study 25762355 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgement
Number of subjects: 1092
Study 25762355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgement and bioimpedance
Number of subjects: 1092
Study 25762533 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (5 µg/kg) administered intravenously
Number of subjects: 60
Study 25762533 — intervention group
Group type: COMPARATOR
Intervention: Baseline heart rate
Number of subjects: 60
Study 25762808 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee intake (self-reported)
Number of subjects: 498
Study 25762808 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-related metabolites (theophylline, caffeine, paraxanthine)
Number of subjects: 498
Study 25763111 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 25
Study 25763783 — intervention group
Group type: EXPERIMENTAL
Intervention: TFV disoproxil fumarate/FTC therapy
Number of subjects: 19
Study 25763789 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy for FGFR2 fusions
Number of subjects: 0
Study 25763831 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 53
Study 25763866 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (150 mg/kg body weight)
Number of subjects: 156
Study 25763866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 25763866 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Number of subjects: 156
Study 25764091 — intervention group
Group type: EXPERIMENTAL
Intervention: PanCan risk prediction models
Number of subjects: 718
Study 25764096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of blood in a single aerobic bottle
Number of subjects: 519
Study 25764096 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mL in aerobic and anaerobic bottles (control)
Number of subjects: 519
Study 25764096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL in a single aerobic bottle
Number of subjects: 519
Study 25765333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.05 mg/kg
Number of subjects: 14
Study 25765333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.1 mg/kg
Number of subjects: 14
Study 25765333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.2 mg/kg
Number of subjects: 14
Study 25765333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.3 mg/kg
Number of subjects: 14
Study 25765333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (all doses)
Number of subjects: 14
Study 25765724 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct diameter cut-off of 3 cm
Number of subjects: 238
Study 25765724 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct diameter cut-off of 3.5 cm
Number of subjects: 238
Study 25765724 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct diameter cut-off of 4 cm
Number of subjects: 238
Study 25766045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TBI
Number of subjects: 439
Study 25766093 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-1-1 dispatcher assessment of OOHCA
Number of subjects: 2260
Study 25766093 — intervention group
Group type: COMPARATOR
Intervention: Dispatchers suspected cardiac arrest in 490 cases not in cardiac arrest
Number of subjects: 2260
Study 25766256 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation analysis (exon 19 deletions and exon 21 L858R point mutation)
Number of subjects: 1113
Study 25766256 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation analysis (exons 18, 20, and 21 excluding L858R)
Number of subjects: 1113
Study 25766256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical factors associated with EGFR mutations
Number of subjects: 1113
Study 25766640 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor (TNF) treatment
Number of subjects: 48
Study 25766898 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 PET imaging using the SUVR method
Number of subjects: 57
Study 25766898 — intervention group
Group type: COMPARATOR
Intervention: (11)C-PBR28 PET imaging using absolute quantitation (VT/fP)
Number of subjects: 57
Study 25767565 — intervention group
Group type: EXPERIMENTAL
Intervention: CCO + SSD
Number of subjects: 55
Study 25767565 — intervention group
Group type: COMPARATOR
Intervention: Control (supportive care + SSD)
Number of subjects: 55
Study 25768439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) 1 mg administered subcutaneously every other day and capecitabine 1000 mg/m2 orally twice a day for 2 weeks on, 1 week off.
Number of subjects: 97
Study 25768439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) with capecitabine in patients with moderate immune-related adverse events (irAEs).
Number of subjects: 97
Study 25768439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) with capecitabine.
Number of subjects: 97
Study 25768671 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline copeptin level >21.4 pmol/L
Number of subjects: 55
Study 25768671 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated copeptin >4.9 pmol/L (at sodium levels >147 mmol/L)
Number of subjects: 55
Study 25768671 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated AVP >1.8 pg/mL
Number of subjects: 55
Study 25768735 — intervention group
Group type: EXPERIMENTAL
Intervention: PASTOR (interprofessional biopsychosocial rehabilitation program)
Number of subjects: 536
Study 25768735 — intervention group
Group type: COMPARATOR
Intervention: MOR (multidisciplinary orthopedic rehabilitation)
Number of subjects: 536
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-releasing silk
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopregnanolone (SAGE-547)
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: AMP-X-0079
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidivarin
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-glucose
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Imepitoin
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: NAX 801-2
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX 0023
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE-217
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Valnoctamide
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sec-butyl-propylacetamide (SPD)
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: VLB-01
Number of subjects: 130
Study 25769377 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 130
Study 25769620 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-bendamustine (G-B)
Number of subjects: 41
Study 25769620 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-fludarabine-cyclophosphamide (G-FC)
Number of subjects: 41
Study 25769789 — intervention group
Group type: EXPERIMENTAL
Intervention: mesenchymal stromal cell-based therapy
Number of subjects: 0
Study 25769961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing homes with 30 GPs or more/100 beds
Number of subjects: 6275
Study 25769961 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents aged ≥ 85 years
Number of subjects: 6275
Study 25769961 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with dementia
Number of subjects: 6275
Study 25769961 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with a statement of 'no psychotropic drug prescription' but had a prescription
Number of subjects: 6275
Study 25770144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (IVR)
Number of subjects: 0
Study 25770144 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with IVR)
Number of subjects: 0
Study 25770355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanfilippo Behavior Rating Scale (SBRS)
Number of subjects: 0
Study 25770405 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWare HVAD System
Number of subjects: 382
Study 25770408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation
Number of subjects: 57
Study 25770676 — intervention group
Group type: COMPARATOR
Intervention: Neoepitope concentrations in patients with idiopathic pulmonary fibrosis (n=189)
Number of subjects: 189
Study 25770676 — intervention group
Group type: COMPARATOR
Intervention: Baseline concentrations of neoepitopes in patients with progressive idiopathic pulmonary fibrosis (n=32)
Number of subjects: 189
Study 25770676 — intervention group
Group type: COMPARATOR
Intervention: Mean concentrations of C1M, C3M, C6M, and CRPM at baseline in patients with idiopathic pulmonary fibrosis (n=134)
Number of subjects: 189
Study 25770676 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal concentrations of six neoepitopes in patients with progressive idiopathic pulmonary fibrosis (n=71)
Number of subjects: 189
Study 25770676 — intervention group
Group type: COMPARATOR
Intervention: Baseline concentrations of C1M and C3A
Number of subjects: 189
Study 25770676 — intervention group
Group type: COMPARATOR
Intervention: Rate of change between baseline and 3 months of six neoepitopes
Number of subjects: 189
Study 25770676 — intervention group
Group type: COMPARATOR
Intervention: Rate of change of CRPM greater than 0 ng/mL per month
Number of subjects: 189
Study 25770690 — intervention group
Group type: COMPARATOR
Intervention: HbA1c levels <5.0, 5.0-5.6 (reference), 5.7-6.4
Number of subjects: 2519
Study 25771041 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% DHEA (prasterone) administered daily intravaginally for 52 weeks
Number of subjects: 521
Study 25771402 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (standard dose: adult 400 mg daily; children 260 mg/m² daily)
Number of subjects: 20
Study 25771402 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (dose escalation regimen: adult 100 mg daily initial dose up to 200 mg daily maximum; children initial dose 65 mg/m² daily up to 130 mg/m² daily)
Number of subjects: 20
Study 25771794 — intervention group
Group type: EXPERIMENTAL
Intervention: abiliti system (closed-loop gastric electrical stimulation)
Number of subjects: 34
Study 25772026 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic profiling
Number of subjects: 0
Study 25772191 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of essential fatty acids (EFA)
Number of subjects: 262
Study 25772191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat sources and fatty acid (FA) intake
Number of subjects: 262
Study 25772191 — intervention group
Group type: EXPERIMENTAL
Intervention: FA compositions of serum lipids
Number of subjects: 262
Study 25772191 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid mead:arachidonic acid ratio
Number of subjects: 262
Study 25772191 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of LA proportions in phospholipids
Number of subjects: 262
Study 25772231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (Neupro) as add-on to oral PD treatment for ≥1 month
Number of subjects: 147
Study 25772231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (Neupro)
Number of subjects: 147
Study 25772541 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation (radiofrequency catheter ablation)
Number of subjects: 27
Study 25772756 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD with FOLFIRI
Number of subjects: 119
Study 25772756 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD with FOLFOX
Number of subjects: 119
Study 25772756 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg QD
Number of subjects: 119
Study 25773763 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (1, 2, and 4 mg/24 h)
Number of subjects: 24
Study 25773763 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h)
Number of subjects: 24
Study 25773763 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 24
Study 25773781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 25773989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SCA
Number of subjects: 61
Study 25774459 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsh PK/PD model
Number of subjects: 12
Study 25774459 — intervention group
Group type: EXPERIMENTAL
Intervention: Schnider PK/PD model
Number of subjects: 12
Study 25774664 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (HOMA-IR ≥2.6)
Number of subjects: 362
Study 25774664 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive group (HOMA-IR <2.6)
Number of subjects: 362
Study 25775506 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Record App (FRapp)
Number of subjects: 18
Study 25775947 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT + treatment-as-usual (TAU)
Number of subjects: 44
Study 25775947 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual (TAU)
Number of subjects: 44
Study 25777337 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy with eltrombopag, pegylated interferon, and ribavirin
Number of subjects: 1268
Study 25777337 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis-related thrombocytopenia
Number of subjects: 1268
Study 25777344 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly sensitive troponin (hsTnI)
Number of subjects: 99
Study 25777344 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI serial measurements
Number of subjects: 99
Study 25777344 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI rising levels
Number of subjects: 99
Study 25777345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg orally b.i.d. with bortezomib 1 mg/m(2) intravenously on days 1, 4, 8, and 11 every 21 days.
Number of subjects: 17
Study 25777357 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy preload (137 kcal)
Number of subjects: 236
Study 25777357 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal snack (430 kcal)
Number of subjects: 236
Study 25777357 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal use of food as reward
Number of subjects: 236
Study 25777357 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 236
Study 25778529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo fucosylation of cord blood cells using fucosyltransferase-VI and guanosine diphosphate fucose for 30 minutes.
Number of subjects: 53
Study 25778529 — intervention group
Group type: COMPARATOR
Intervention: Historical controls receiving double unmanipulated cord blood transplantation.
Number of subjects: 53
Study 25778850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 18 months
Number of subjects: 86
Study 25779580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric population model with Bayesian adaptive control algorithm
Number of subjects: 33
Study 25779580 — intervention group
Group type: EXPERIMENTAL
Intervention: Using only trough concentrations for Bayesian posterior parameter values
Number of subjects: 33
Study 25779580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample collected at optimal time of 4 h after dose, in addition to trough concentration
Number of subjects: 33
Study 25779713 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler sonography
Number of subjects: 80
Study 25779713 — intervention group
Group type: COMPARATOR
Intervention: Gray-scale sonography
Number of subjects: 80
Study 25779713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularity measurement
Number of subjects: 80
Study 25779713 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall thickness measurement
Number of subjects: 80
Study 25780077 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 vaccine
Number of subjects: 200
Study 25780349 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-associated acute kidney injury (CA-AKI) patients
Number of subjects: 335
Study 25780349 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher APACHE II scores
Number of subjects: 335
Study 25780518 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG) stimulation
Number of subjects: 60
Study 25780518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HCG stimulation)
Number of subjects: 60
Study 25781361 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year outpatient intervention program based on exercise, behavior, and nutrition therapy
Number of subjects: 60
Study 25782122 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral anticoagulants (NOACs)
Number of subjects: 4100
Study 25782122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 4100
Study 25782122 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 4100
Study 25782184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent with biodegradable polymer
Number of subjects: 1356
Study 25782401 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician assessment of dry eye severity using Dry Eye Workshop severity grading (levels 1-4)
Number of subjects: 466
Study 25782401 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient assessment using Ocular Surface Disease Index questionnaire
Number of subjects: 466
Study 25782401 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician assessment of treatment response using Clinical Global Impression scale
Number of subjects: 466
Study 25782401 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient assessment of treatment response using Subject Global Assessment scale
Number of subjects: 466
Study 25782401 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between clinician and patient assessments
Number of subjects: 466
Study 25782757 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved health status (SGRQ score change >4 units)
Number of subjects: 2138
Study 25782757 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable health status (SGRQ score change ≤4 units)
Number of subjects: 2138
Study 25783622 — intervention group
Group type: EXPERIMENTAL
Intervention: High cfPWV
Number of subjects: 682
Study 25783622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PPA
Number of subjects: 682
Study 25783622 — intervention group
Group type: EXPERIMENTAL
Intervention: High HR
Number of subjects: 682
Study 25783622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ADLs
Number of subjects: 682
Study 25783622 — intervention group
Group type: COMPARATOR
Intervention: BP
Number of subjects: 682
Study 25783834 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair
Number of subjects: 160
Study 25783834 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain during sexual activity
Number of subjects: 160
Study 25784682 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus melphalan and prednisone (CMP) at the maximal tolerated dose (MTD) of 36 mg/m².
Number of subjects: 68
Study 25784682 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus melphalan and prednisone (CMP) at the MTD of 36 mg/m².
Number of subjects: 68
Study 25784749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk model using early neonatal risk factors
Number of subjects: 1469
Study 25784749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk model using risk factors at 36 weeks' postmenstrual age
Number of subjects: 1469
Study 25784749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk model using sociodemographic variables
Number of subjects: 1469
Study 25784948 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 80
Study 25784948 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 80